Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
-
-
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
-
-
(4-phenyl-1,2-oxazol-5-yl)methanol
-
-
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
-
-
1-(2-hydroxy-4-methylphenyl)-3-(2-methoxyphenyl)propane-1,3-dione
-
-
1-(2-hydroxy-4-methylphenyl)-3-{2-[(propan-2-yl)oxy]phenyl}propane-1,3-dione
-
-
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromothiophen-2-yl)-2-(3-methyl-1,4-dihydronaphthalen-2-yl)ethan-1-one
most potent inhibitor capable of blocking both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) activity, with the IC50 value for BT-549 cells at 0.00342 mM
-
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(cyclopropylmethyl)-5-(1H-indol-3-yl)-1H-benzotriazole
-
-
1-(cyclopropylmethyl)-6-(1H-indol-3-yl)-1H-benzotriazole
-
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
-
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
-
-
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
-
-
2-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]-N,N-dimethylethan-1-amine
-
-
2-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetamide
-
-
2-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]-N,N-dimethylethan-1-amine
-
-
2-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetamide
-
-
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
3-methyl-4-phenyl-1,2-oxazol-5-amine
-
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
3-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]propane-1,2-diol
-
-
3-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]propane-1,2-diol
-
-
4-(1H-pyrazol-1-yl)-1,2-oxazol-5-amine
-
-
4-(3-chlorophenyl)-1,2-oxazol-5-amine
-
-
4-(3-methoxyphenyl)-1,2-oxazol-5-amine
-
-
4-(3-methyl-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
-
-
4-(4-chlorophenyl)-1,2-oxazol-5-amine
-
-
4-(4-fluoro-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
-
-
4-(4-fluorophenyl)-1,2-oxazol-5-amine
-
-
4-(4-methyl-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
-
-
4-(pyridin-2-yl)-1,2-oxazol-5-amine
-
-
4-(pyridin-3-yl)-1,2-oxazol-5-amine
-
-
4-(thiophen-2-yl)-1,2-oxazol-5-amine
-
-
4-(thiophen-3-yl)-1,2-oxazol-5-amine
-
-
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
-
-
4-cyclohexyl-1,2-oxazol-5-amine
-
-
4-cyclopentyl-1,2-oxazol-5-amine
-
-
4-phenyl-1,2-oxazol-5-amine
-
-
4-phenyl-1,2-thiazol-5-amine
-
-
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
-
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
-
-
5-(1H-indol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-methyl-1H-benzotriazol-4-amine
-
-
5-(1H-indol-3-yl)-1-methyl-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[(oxolan-2-yl)methyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[(oxolan-3-yl)methyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[(piperidin-4-yl)methyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-1-[2-(pyrrolidin-3-yl)ethyl]-1H-benzotriazole
-
-
5-(1H-indol-3-yl)-2-methyl-2H-benzotriazol-4-amine
-
-
5-(1H-indol-3-yl)-2-methyl-2H-benzotriazole
-
-
5-(6-fluoro-1H-indol-3-yl)-1-methyl-1H-benzotriazole
-
-
5-(6-fluoro-1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
-
-
5-phenyl-1,2,3-thiadiazol-4-amine
potent tryptophan 2,3-dioxygenase 2 inhibitor with modest selectivity over indolamine 2,3-dioxygenase 1 and with improved human whole blood stability
-
6-(1H-indol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-methyl-1H-benzotriazol-7-amine
-
-
6-(1H-indol-3-yl)-1-methyl-1H-[1,2,3]triazolo[4,5-b]pyridine
-
-
6-(1H-indol-3-yl)-1-methyl-7-nitro-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[(oxolan-2-yl)methyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[(oxolan-3-yl)methyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[(piperidin-4-yl)methyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[(pyrrolidin-3-yl)methyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-1H-benzotriazole
-
-
6-(1H-indol-3-yl)-2-methyl-2H-[1,2,3]triazolo[4,5-b]pyridine
-
-
6-(1H-indol-3-yl)-3-methyl-3H-[1,2,3]triazolo[4,5-b]pyridine
-
-
6-(1H-indol-3-yl)isoquinoline
-
-
6-(1H-indol-3-yl)quinazoline
-
-
6-bromo-1H-indazol-4-amine
-
-
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
-
-
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
-
-
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-fluoro-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-1H-indole
-
-
6-fluoro-3-[(E)-2-(pyridin-3-yl)ethenyl]-1H-indole
-
-
7-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one
-
-
7-(1H-indol-3-yl)isoquinoline
-
-
7-(1H-indol-3-yl)quinazoline
-
-
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
-
-
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
-
-
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
-
-
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
-
-
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
-
-
N-methyl-4-phenyl-1,2-oxazol-5-amine
-
-
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
-
-
[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetic acid
-
-
[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetic acid
-
-
4-(3-chlorophenyl)-imidazole
-
-
4-chlorophenyl-1,2,3-triazol-4-amine
-
-
isatin
-
mechanism of inhibition
additional information
identification of substituted naphthotriazolediones as tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening, homology modeling and virtual screening, ligand docking analysis, overview
-
additional information
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
-
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
the enzymatic and cellular assays are influenced by many factors including detection product, reaction time and culture medium, which may cause the inconsistency of enzymatic and cellular inhibitory activities of test compounds. The TDO IC50 values of all the test compounds derived from NFK assay are 2-3 times higher than that of Kyn adduct assay
-
additional information
-
the enzymatic and cellular assays are influenced by many factors including detection product, reaction time and culture medium, which may cause the inconsistency of enzymatic and cellular inhibitory activities of test compounds. The TDO IC50 values of all the test compounds derived from NFK assay are 2-3 times higher than that of Kyn adduct assay
-
additional information
-
isatin derivatives analysis as a class of TDO inhibitors, structure-activity relationships and molecular docking studies, and optimized the inhibition potency of isatin derivatives by over 130fold, overview. Hydrogen bond interactions between the compound and key active site residues of TDO, freedom upon rotation of the C3 chemical moiety and the presence of chlorines in the benzene ring of the compound comprise the properties that an isatin-based inhibitor requires to effectively inhibit the enzymatic activity of enzyme TDO
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Role of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase in Patients with Recurrent Miscarriage.
Adenocarcinoma
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Adenocarcinoma
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Adenocarcinoma of Lung
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Adenocarcinoma of Lung
B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
Adenocarcinoma of Lung
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Alzheimer Disease
Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.
Alzheimer Disease
Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Alzheimer Disease
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.
Alzheimer Disease
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Alzheimer Disease
The Effect of Tryptophan 2,3-Dioxygenase Inhibition on Kynurenine Metabolism and Cognitive Function in the APP23 Mouse Model of Alzheimer's Disease.
Anemia, Hemolytic
[Activity of key enzymes of heme metabolism and cytochrome P-450 content in the rat liver in experimental rhabdomyolysis and hemolytic anemia]
Arthritis
B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model.
Arthritis
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Aspergillosis
Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans.
Asthma
Neopterin Levels and Indoleamine 2,3-Dioxygenase Activity as Biomarkers of Immune System Activation and Childhood Allergic Diseases.
Asthma
Tryptophan Metabolism in Allergic Disorders.
Atherosclerosis
The proatherosclerotic function of indoleamine 2, 3-dioxygenase 1 in the developmental stage of atherosclerosis.
Autoimmune Diseases
Amino acid metabolism as drug target in autoimmune diseases.
Autoimmune Diseases
An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-?: potential therapeutic use in autoimmune diseases.
Brain Neoplasms
The kynurenine pathway in brain tumor pathogenesis.
Breast Neoplasms
A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
Breast Neoplasms
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Breast Neoplasms
Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets.
Breast Neoplasms
Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy.
Breast Neoplasms
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.
Breast Neoplasms
TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Carcinogenesis
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Carcinoma
Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Carcinoma
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Carcinoma
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Carcinoma
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon ? signature.
Carcinoma
High IDO-1 Expression in Tumor Endothelial Cells is Associated with Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Carcinoma
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
Carcinoma
Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Carcinoma
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Carcinoma
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment.
Carcinoma
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.
Carcinoma
Subcutaneous inoculation position affects the immune environment in CT26 carcinomas.
Carcinoma
Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Carcinoma
Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Carcinoma, Adenosquamous
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Carcinoma, Hepatocellular
Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression.
Carcinoma, Hepatocellular
Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Novel conjugates with dual suppression of glutathione S-transferases and tryptophan-2,3-dioxygenase activities for improving hepatocellular carcinoma therapy.
Carcinoma, Hepatocellular
Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.
Carcinoma, Medullary
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment.
Carcinoma, Non-Small-Cell Lung
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Carcinoma, Non-Small-Cell Lung
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Carcinoma, Non-Small-Cell Lung
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Carcinoma, Non-Small-Cell Lung
Investigation of indolamine 2, 3 dioxygenase (IDO-1) gene expression by real-time PCR among patients with lung cancer.
Carcinoma, Renal Cell
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Carcinoma, Renal Cell
High IDO-1 Expression in Tumor Endothelial Cells is Associated with Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Carcinoma, Squamous Cell
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon ? signature.
Carcinoma, Squamous Cell
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Carcinosarcoma
Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Cardiomegaly
Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
Cluster Headache
The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
Colitis
Gut microorganisms and their metabolites modulate the severity of acute colitis in a tryptophan metabolism-dependent manner.
Colitis
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
Colorectal Neoplasms
1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.
Colorectal Neoplasms
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.
Colorectal Neoplasms
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer.
Colorectal Neoplasms
Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy.
Colorectal Neoplasms
Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer.
Colorectal Neoplasms
Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer.
Colorectal Neoplasms
Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system.
Demyelinating Diseases
Effects of Lactobacillus casei Strain T2 (IBRC-M10783) on the Modulation of Th17/Treg and Evaluation of miR-155, miR-25, and IDO-1 Expression in a Cuprizone-Induced C57BL/6 Mouse Model of Demyelination.
Dermatitis, Atopic
Neopterin Levels and Indoleamine 2,3-Dioxygenase Activity as Biomarkers of Immune System Activation and Childhood Allergic Diseases.
Diabetes Mellitus
Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression.
Diabetes Mellitus, Type 1
Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.
Diabetes Mellitus, Type 1
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.
Diabetes Mellitus, Type 2
Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression.
Encephalitis
Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels.
Encephalitis, Herpes Simplex
Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels.
Encephalitis, Viral
Indoleamine 2,3-dioxygenase 1 is upregulated in activated microglia in mice cerebellum during acute viral encephalitis.
Endometriosis
IL-1? Increases Expression of Tryptophan 2,3-dioxygenase and Stimulates Tryptophan Catabolism in Endometrioma Stromal Cells.
Esophageal Neoplasms
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
Esophageal Squamous Cell Carcinoma
Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
Esophageal Squamous Cell Carcinoma
Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Glioblastoma
Hypoxia Inducible Factor 1? Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
Glioblastoma
Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Glioblastoma
Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells.
Glioma
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
Glioma
Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP?.
Glioma
Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Glioma
Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells.
Glioma
Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
Glioma
Involvement of the kynurenine pathway in human glioma pathophysiology.
Glioma
Shaping the glioma immune microenvironment through tryptophan metabolism.
Glioma
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Glioma
The aryl hydrocarbon receptor in tumor immunity.
Glioma
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Glioma
Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.
Glucose Intolerance
Comparison of effects of nicotinic acid or tryptophan on tryptophan 2,3-dioxygenase in acute and chronic studies.
Graft vs Host Disease
IDO1 scavenges reactive oxygen species in myeloid-derived suppressor cells to prevent graft-versus-host disease.
Hepatitis
Liver tryptophan 2,3-dioxygenase in the mouse hepatitis virus (MHV-A59) model.
Hepatitis
The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO).
Hepatitis C
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer.
Herpes Simplex
Indoleamine 2,3-dioxygenase 1 in corneal endothelial cells limits herpes simplex virus type 1-induced acquired immune response.
HIV Infections
Increased Tryptophan Catabolism Is Associated With Increased Frequency of CD161+Tc17/MAIT Cells and Lower CD4+ T-Cell Count in HIV-1 Infected Patients on cART After 2 Years of Follow-Up.
HIV Infections
Increased Tryptophan Catabolism is Associated with Increased Frequency of CD161+Tc17/MAIT Cells, and Lower CD4+ T cell Count in HIV-1 infected Patients on cART after Two Years of Follow-up.
Hypertension
The activation of the kynurenine pathway in a rat model with renovascular hypertension.
Hypotension
Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Infections
Benzo[b]quinolizinium Derivatives Have a Strong Antimalarial Activity and Inhibit Indoleamine Dioxygenase.
Infections
Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.
Infections
Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection.
Infections
Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection.
Infections
M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection.
Infections
The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO).
Infections
The High-Risk Human Papillomavirus E6 Oncogene Exacerbates the Negative Effect of Tryptophan Starvation on the Development of Chlamydia trachomatis.
Infections
Tryptophan 2,3-dioxygenase activity in turkey poults infected with Bordetella avium.
Insulin Resistance
Attenuation of high sucrose diet-induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster vermilion mutants.
Kidney Neoplasms
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.
Leiomyoma
Tryptophan catabolism is dysregulated in leiomyomas.
Leprosy
Mycobacterium leprae induces a tolerogenic profile in monocyte-derived dendritic cells via TLR2 induction of IDO.
Leukemia
Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
Leukemia, Myeloid, Acute
A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
Leukemia, Myeloid, Acute
Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
Liver Cirrhosis
Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Liver Cirrhosis
Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis.
Liver Cirrhosis
Mutual antagonism between indoleamine 2,3-dioxygenase 1 and nuclear factor E2-related factor 2 regulates the maturation status of DCs in liver fibrosis.
Liver Diseases
A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases.
Lung Neoplasms
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Lung Neoplasms
Class A CpG oligodeoxynucleotide inhibits IFN-?-induced signaling and apoptosis in lung cancer.
Lung Neoplasms
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Lung Neoplasms
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
Lung Neoplasms
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2, 3-Dioxygenase with Therapeutic Activity in LLC tumor-bearing Mice.
Lung Neoplasms
Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion.
Lung Neoplasms
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Lung Neoplasms
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Lung Neoplasms
Investigation of indolamine 2, 3 dioxygenase (IDO-1) gene expression by real-time PCR among patients with lung cancer.
Lung Neoplasms
Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.
Lymphoma, B-Cell
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Lymphoma, Large B-Cell, Diffuse
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Lymphoma, Non-Hodgkin
Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Lymphoma, T-Cell, Cutaneous
Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.
Malaria
Purification and biochemical characterization of a recombinant Anopheles gambiae tryptophan 2,3-dioxygenase expressed in Escherichia coli.
Malaria, Cerebral
Benzo[b]quinolizinium Derivatives Have a Strong Antimalarial Activity and Inhibit Indoleamine Dioxygenase.
Melanoma
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Melanoma
Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma.
Melanoma
Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion.
Melanoma
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.
Melanoma
Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Melanoma
The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Meningioma
Altered tryptophan metabolism in human meningioma.
Meningioma
In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.
Meningioma
Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
Multiple Myeloma
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.
Multiple Sclerosis
Polyamines and Kynurenines at the Intersection of Immune Modulation.
Multiple Sclerosis
Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.
Muscular Dystrophy, Duchenne
Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.
Mycoses
Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi.
Nasal Polyps
Functional role of kynurenine and aryl hydrocarbon receptor axis in chronic rhinosinusitis with nasal polyps.
Neoplasm Metastasis
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Neoplasm Metastasis
Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancer.
Neoplasm Metastasis
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.
Neoplasm Metastasis
Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets.
Neoplasm Metastasis
Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Neoplasm Metastasis
Polyphenols inhibit indoleamine 3,5-dioxygenase-1 enzymatic activity--a role of immunomodulation in chemoprevention.
Neoplasm Metastasis
Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation.
Neoplasms
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
Neoplasms
4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Neoplasms
4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Neoplasms
A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma.
Neoplasms
A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Neoplasms
A patent review of IDO1 inhibitors for cancer.
Neoplasms
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Neoplasms
A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Neoplasms
A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.
Neoplasms
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.
Neoplasms
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry.
Neoplasms
Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Neoplasms
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Neoplasms
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Neoplasms
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase.
Neoplasms
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Neoplasms
Association of breast carcinoma growth with a non-canonical axis of IFN?/IDO1/TSP1.
Neoplasms
Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Neoplasms
Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment.
Neoplasms
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Neoplasms
Blocking IDO1 Helps Shrink Bladder, Cervical Tumors.
Neoplasms
Capping Silica Nanoparticles with Tryptophan-Mediated Cucurbit[8]uril Complex for Targeted Intracellular Drug Delivery Triggered by Tumor-Overexpressed IDO1 Enzyme.
Neoplasms
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Neoplasms
Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
Neoplasms
Clinical significance of tryptophan catabolism in follicular lymphoma.
Neoplasms
Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer.
Neoplasms
Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP?.
Neoplasms
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Neoplasms
Crystal structure of Drosophila melanogaster tryptophan 2,3-dioxygenase reveals insights into substrate recognition and catalytic mechanism.
Neoplasms
Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors.
Neoplasms
Current Challenges for IDO2 as Target in Cancer Immunotherapy.
Neoplasms
Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors.
Neoplasms
Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors.
Neoplasms
Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
Neoplasms
Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
Neoplasms
Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors.
Neoplasms
Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
Neoplasms
Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Neoplasms
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Neoplasms
Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
Neoplasms
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
Neoplasms
Dexamethasone Induces the Expression and Function of Tryptophan-2-3-Dioxygenase in SK-MEL-28 Melanoma Cells.
Neoplasms
Different effects of tryptophan 2,3-dioxygenase inhibition on SK-Mel-28 and HCT-8 cancer cell lines.
Neoplasms
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Neoplasms
Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Neoplasms
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Neoplasms
Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Neoplasms
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
Neoplasms
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.
Neoplasms
Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties.
Neoplasms
Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Neoplasms
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors.
Neoplasms
Discovery of IDO1 and DNA dual targeting antitumor agents.
Neoplasms
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Neoplasms
Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
Neoplasms
Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
Neoplasms
Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.
Neoplasms
Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo.
Neoplasms
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Neoplasms
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2, 3-Dioxygenase with Therapeutic Activity in LLC tumor-bearing Mice.
Neoplasms
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon ? signature.
Neoplasms
Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.
Neoplasms
Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancer.
Neoplasms
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
Neoplasms
Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.
Neoplasms
Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon ? gene transfer on interferon ?-mediated antitumor activity.
Neoplasms
Eicosapentaenoic acid reduces indoleamine 2,3-dioxygenase 1 expression in tumor cells.
Neoplasms
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Neoplasms
Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Neoplasms
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.
Neoplasms
Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis.
Neoplasms
Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets.
Neoplasms
Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.
Neoplasms
Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy.
Neoplasms
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity.
Neoplasms
Forty-three key gene expressions involved in the effect of indoleamine 2,3-dioxygenase 1 expression on cancer prognosis may be a potential indoleamine 2,3-dioxygenase 1 inhibitor biomarker.
Neoplasms
Fragment-based approach to identify IDO1 inhibitor building blocks.
Neoplasms
Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion.
Neoplasms
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.
Neoplasms
Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8?+ T Cells and Differentiated ?? T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules.
Neoplasms
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer.
Neoplasms
Heme enzyme patterns in genetically and chemically induced mouse liver tumors.
Neoplasms
Heme enzyme patterns in rat liver nodules and tumors.
Neoplasms
High IDO-1 Expression in Tumor Endothelial Cells is Associated with Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Neoplasms
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Neoplasms
High-resolution structures of inhibitor complexes of human indoleamine 2,3-dioxygenase 1 in a new crystal form.
Neoplasms
Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment.
Neoplasms
Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Neoplasms
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Neoplasms
IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Neoplasms
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.
Neoplasms
Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma.
Neoplasms
Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue-Focus on RAGE and IDO1.
Neoplasms
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
Neoplasms
Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1.
Neoplasms
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Neoplasms
INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IS UPREGULATED IN THYROID CARCINOMA AND DRIVES THE DEVELOPMENT OF AN IMMUNOSUPPRESSANT TUMOR MICROENVIRONMENT.
Neoplasms
Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
Neoplasms
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
Neoplasms
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Neoplasms
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Neoplasms
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Neoplasms
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Neoplasms
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Neoplasms
Induction of tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1 and U937.
Neoplasms
Induction of tryptophan hydroxylase in the liver of s.c. tumor model of prostate cancer.
Neoplasms
Influence of the presence of the heme cofactor on the JK-loop structure in indoleamine 2,3-dioxygenase 1.
Neoplasms
Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice.
Neoplasms
Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase activity by fatty acids and prostaglandins: A structure function analysis.
Neoplasms
Inhibition of photodynamic therapy induced-immunosuppression with aminolevulinic acid leads to enhanced outcomes of tumors and pre-cancerous lesions.
Neoplasms
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Neoplasms
Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells.
Neoplasms
Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity.
Neoplasms
Inhibitory investigation of niacin derivatives on metalloenzyme indoleamine 2,3-dioxygenase 1 for its immunomodulatory function.
Neoplasms
Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.
Neoplasms
Investigation of indolamine 2, 3 dioxygenase (IDO-1) gene expression by real-time PCR among patients with lung cancer.
Neoplasms
Involvement of the kynurenine pathway in human glioma pathophysiology.
Neoplasms
Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Neoplasms
LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.
Neoplasms
Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier.
Neoplasms
Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1.
Neoplasms
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment.
Neoplasms
Melatonin in cancer patients and in tumor-bearing animals.
Neoplasms
Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy.
Neoplasms
Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase.
Neoplasms
Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase.
Neoplasms
N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase.
Neoplasms
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.
Neoplasms
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Neoplasms
Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
Neoplasms
Novel conjugates with dual suppression of glutathione S-transferases and tryptophan-2,3-dioxygenase activities for improving hepatocellular carcinoma therapy.
Neoplasms
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
Neoplasms
Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold.
Neoplasms
OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
Neoplasms
On-line screening of indoleamine 2,3-dioxygenase 1 inhibitors by partial filling capillary electrophoresis combined with rapid polarity switching.
Neoplasms
Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.
Neoplasms
Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer.
Neoplasms
Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay.
Neoplasms
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Neoplasms
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Neoplasms
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Neoplasms
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Neoplasms
Polyphenols inhibit indoleamine 3,5-dioxygenase-1 enzymatic activity--a role of immunomodulation in chemoprevention.
Neoplasms
Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Neoplasms
Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
Neoplasms
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
Neoplasms
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.
Neoplasms
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.
Neoplasms
Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Neoplasms
Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Neoplasms
Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators.
Neoplasms
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
Neoplasms
Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors.
Neoplasms
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Neoplasms
Reciprocal Regulation Between Indoleamine 2,3-Dioxigenase 1 and Notch1 Involved in Radiation Response of Cervical Cancer Stem Cells.
Neoplasms
Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells.
Neoplasms
Retraction of "Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway".
Neoplasms
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Neoplasms
Self-Amplified Drug Delivery with Light-Inducible Nanocargoes to Enhance Cancer Immunotherapy.
Neoplasms
Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy.
Neoplasms
Self-Delivery Photo-Immune Stimulators for Photodynamic Sensitized Tumor Immunotherapy.
Neoplasms
Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion.
Neoplasms
Sheddable Prodrug Vesicles Combating Adaptive Immune Resistance for Improved Photodynamic Immunotherapy of Cancer.
Neoplasms
Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.
Neoplasms
Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1.
Neoplasms
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Neoplasms
Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer.
Neoplasms
Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1.
Neoplasms
Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1.
Neoplasms
Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Neoplasms
Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Neoplasms
Systematic study of imidazoles inhibiting IDO1 via the integration of molecular mechanics and quantum mechanics calculations.
Neoplasms
Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.
Neoplasms
Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation.
Neoplasms
Targeting the Inhibition of Tryptophan 2,3-Dioxygenase (TDO-2) for Cancer Treatment.
Neoplasms
TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
Neoplasms
TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Neoplasms
TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.
Neoplasms
The aryl hydrocarbon receptor in tumor immunity.
Neoplasms
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).
Neoplasms
The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Neoplasms
The Interactions Between Kynurenine, Folate, Methionine and Pteridine Pathways in Obesity.
Neoplasms
The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
Neoplasms
The kynurenine pathway in brain tumor pathogenesis.
Neoplasms
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.
Neoplasms
The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by ?-PD-L1 or ?-IL6 antibodies.
Neoplasms
The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
Neoplasms
The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.
Neoplasms
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Neoplasms
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators.
Neoplasms
Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.
Neoplasms
Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.
Neoplasms
Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
Neoplasms
Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Neoplasms
Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives.
Neoplasms
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Neoplasms
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Neoplasms
Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients.
Neoplasms
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Neoplasms
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Neoplasms
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRP? infiltration after denosumab treatment.
Neoplasms
Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.
Neoplasms
Unconventional [2 + 3] Cyclization Involving [1,4]-Sulfonyl Transfer to Construct Polysubstituted Fluorazones as Inhibitors of Indoleamine 2,3-Dioxygenase 1.
Neoplasms
Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Neoplasms
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Neoplasms
Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation.
Neoplasms
Viral-induced Modulation of Multiple Checkpoint Proteins in Cancers.
Neoplasms
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
Neoplastic Cells, Circulating
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.
Nervous System Diseases
Ameliorative effect of fisetin against lipopolysaccharide and restraint stress-induced behavioral deficits via modulation of NF-?B and IDO-1.
Nervous System Diseases
Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors.
Nervous System Diseases
Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors.
Neuralgia
Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice.
Neuralgia
The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
Neurodegenerative Diseases
Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Neurodegenerative Diseases
Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives.
Neurodegenerative Diseases
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Neuroinflammatory Diseases
Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression.
Neuroinflammatory Diseases
IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease.
Neuroinflammatory Diseases
M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus.
Neuroinflammatory Diseases
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.
Obesity
Associations Among Obesity, Inflammation, and Tryptophan Catabolism in Pregnancy.
Obesity
Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF?, and IDO1.
Obesity, Maternal
Associations Among Obesity, Inflammation, and Tryptophan Catabolism in Pregnancy.
Ovarian Neoplasms
Tryptophan catabolism in epithelial ovarian carcinoma.
Pancreatic Neoplasms
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Papilloma
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer.
Papillomavirus Infections
Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Parkinson Disease
IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease.
Parkinson Disease
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Persistent Infection
Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1.
Porphyrias
Effects of acute carbamazepine administration on haem metabolism in rat liver.
Porphyrias, Hepatic
Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
Prostatic Neoplasms
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Psoriasis
Indoleamine 2,3-Dioxygenase 2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation.
Psoriasis
Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated.
Purpura, Thrombocytopenic, Idiopathic
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.
Rhabdomyolysis
Free heme pool and activity of key enzyme of heme synthesis in the rat liver under action of agents affecting reduced glutathione level.
Rhinitis, Allergic
Neopterin Levels and Indoleamine 2,3-Dioxygenase Activity as Biomarkers of Immune System Activation and Childhood Allergic Diseases.
Rhinitis, Allergic
Tryptophan Metabolism in Allergic Disorders.
Sarcoma
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.
Seizures
Indoleamine 2,3-dioxygenase 1 deletion promotes Theiler's virus-induced seizures in C57BL/6J mice.
Sepsis
Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs.
Sepsis
Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Shock, Septic
Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Squamous Cell Carcinoma of Head and Neck
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon ? signature.
Squamous Cell Carcinoma of Head and Neck
Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.
Starvation
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.
Starvation
Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1.
Starvation
Role of indoleamine 2,3-dioxygenase in testicular immune-privilege.
Starvation
The influence of starvation and tryptophan administration on the metabolism of phenylalanine, tyrosine and tryptophan in isolated rat liver cells.
Thrombosis
Indoleamine 2,3-dioxygenase 1 in coronary atherosclerotic plaque enhances tissue factor expression in activated macrophages.
Thyroid Neoplasms
INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IS UPREGULATED IN THYROID CARCINOMA AND DRIVES THE DEVELOPMENT OF AN IMMUNOSUPPRESSANT TUMOR MICROENVIRONMENT.
Thyroiditis, Autoimmune
Prunella vulgaris L. attenuates experimental autoimmune thyroiditis by inducing indoleamine 2,3-dioxygenase 1 expression and regulatory T cell expansion.
Tourette Syndrome
Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders.
Triple Negative Breast Neoplasms
Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression.
Triple Negative Breast Neoplasms
Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.
tryptophan 2,3-dioxygenase deficiency
Hypertryptophanemia due to tryptophan 2,3-dioxygenase deficiency.
tryptophan 2,3-dioxygenase deficiency
Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
tryptophan 2,3-dioxygenase deficiency
Indoleamine 2,3-Dioxygenase 2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation.
Tuberculosis
M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection.
Urinary Bladder Neoplasms
Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer.
Urinary Bladder Neoplasms
MicroRNA-153 Decreases Tryptophan Catabolism and Inhibits Angiogenesis in Bladder Cancer by Targeting Indoleamine 2,3-Dioxygenase 1.
Urinary Bladder Neoplasms
Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.
Urinary Bladder Neoplasms
Tryptophan-kynurenine ratio as a biomarker of bladder cancer.
Uterine Cervical Neoplasms
Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Virus Diseases
Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors.
Virus Diseases
Viral-induced Modulation of Multiple Checkpoint Proteins in Cancers.
Vitamin B 6 Deficiency
Multiple roles of haem in cystathionine ?-synthase activity: implications for hemin and other therapies of acute hepatic porphyria.
Vitamin B 6 Deficiency
The effect of pyridoxine deficiency on the metabolism of the aromatic amino acids by isolated rat liver cells.
Zika Virus Infection
Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0004
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.01124
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.03916
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.08419
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.03324
(1R,2S)-2-[[(6-bromo-1-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00004
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
shows efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-Parkinson's disease medicine, 22°C, pH 6.5
-
0.00019
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
Homo sapiens
22°C, pH 6.5
-
0.00013
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00041
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00009
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00003
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0044
(4-phenyl-1,2-oxazol-5-yl)methanol
Homo sapiens
pH and temperature not specified in the publication
-
0.00121
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.000561
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000768
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000711
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000059
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00003
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001586
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00738
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001088
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000176
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000209
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.0135
1-(cyclopropylmethyl)-5-(1H-indol-3-yl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.25
-
0.0039
1-(cyclopropylmethyl)-6-(1H-indol-3-yl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.26
-
0.00015
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
0.001745
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00646
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00042
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00045
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00018
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
Homo sapiens
pH and temperature not specified in the publication
-
0.000048
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000116
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000108
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000145
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
Homo sapiens
pH 8.0, 37°C
0.00338
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.1477
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
Homo sapiens
22°C, pH 6.5
-
0.00204
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00033
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.0369
2-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]-N,N-dimethylethan-1-amine
Homo sapiens
37°C, pH 6.31
-
0.00162
2-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetamide
Homo sapiens
37°C, pH 6.27
-
0.0246
2-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]-N,N-dimethylethan-1-amine
Homo sapiens
37°C, pH 6.32
-
0.00068
2-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetamide
Homo sapiens
37°C, pH 6.28
-
0.00012
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.025
3-methyl-4-phenyl-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00009
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.000167
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.017
3-[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]propane-1,2-diol
Homo sapiens
37°C, pH 6.46
-
0.0252
3-[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]propane-1,2-diol
Homo sapiens
37°C, pH 6.47
-
0.00029
4-(1H-pyrazol-1-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0005
4-(3-chlorophenyl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0031
4-(3-methoxyphenyl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0016
4-(3-methyl-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00083
4-(4-chlorophenyl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00034
4-(4-fluoro-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00058
4-(4-fluorophenyl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0016
4-(4-methyl-1H-pyrazol-1-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0017
4-(pyridin-2-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.0023
4-(pyridin-3-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.000029
4-(thiophen-2-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.000028
4-(thiophen-3-yl)-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.02702
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
Homo sapiens
22°C, pH 6.5
-
0.0078
4-cyclohexyl-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00064
4-cyclopentyl-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00014
4-phenyl-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.018
4-phenyl-1,2-thiazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.01286
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.000181
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.000312
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.00185
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.015
5-(1H-indol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.23
-
0.00501
5-(1H-indol-3-yl)-1-methyl-1H-benzotriazol-4-amine
Homo sapiens
37°C, pH 6.17
-
0.00387
5-(1H-indol-3-yl)-1-methyl-1H-benzotriazole
Homo sapiens
37°C, pH 6.13
-
0.0369
5-(1H-indol-3-yl)-1-[(oxolan-2-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.35
-
0.0441
5-(1H-indol-3-yl)-1-[(oxolan-3-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.33
-
0.01773
5-(1H-indol-3-yl)-1-[(piperidin-4-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.39
-
0.1186
5-(1H-indol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.37
-
0.0249
5-(1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.43
-
0.0261
5-(1H-indol-3-yl)-1-[2-(pyrrolidin-3-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.41
-
0.00385
5-(1H-indol-3-yl)-2-methyl-2H-benzotriazol-4-amine
Homo sapiens
37°C, pH 6.16
-
0.004
5-(1H-indol-3-yl)-2-methyl-2H-benzotriazole
Homo sapiens
37°C, pH 6.12
-
0.0011
5-(6-fluoro-1H-indol-3-yl)-1-methyl-1H-benzotriazole
Homo sapiens
37°C, pH 6.14
-
0.045
5-(6-fluoro-1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.44
-
0.0019
6-(1H-indol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.24
-
0.00393
6-(1H-indol-3-yl)-1-methyl-1H-benzotriazol-7-amine
Homo sapiens
37°C, pH 6.18
-
0.00908
6-(1H-indol-3-yl)-1-methyl-1H-[1,2,3]triazolo[4,5-b]pyridine
Homo sapiens
37°C, pH 6.21
-
0.00132
6-(1H-indol-3-yl)-1-methyl-7-nitro-1H-benzotriazole
Homo sapiens
37°C, pH 6.22
-
0.0211
6-(1H-indol-3-yl)-1-[(oxolan-2-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.36
-
0.0219
6-(1H-indol-3-yl)-1-[(oxolan-3-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.34
-
0.02551
6-(1H-indol-3-yl)-1-[(piperidin-4-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.40
-
0.04565
6-(1H-indol-3-yl)-1-[(pyrrolidin-3-yl)methyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.42
-
0.0526
6-(1H-indol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.38
-
0.0052
6-(1H-indol-3-yl)-1-[2-(piperazin-1-yl)ethyl]-1H-benzotriazole
Homo sapiens
37°C, pH 6.45
-
0.002 - 0.00602
6-(1H-indol-3-yl)-1H-benzotriazole
-
0.01306
6-(1H-indol-3-yl)-2-methyl-2H-[1,2,3]triazolo[4,5-b]pyridine
Homo sapiens
37°C, pH 6.19
-
0.00783
6-(1H-indol-3-yl)-3-methyl-3H-[1,2,3]triazolo[4,5-b]pyridine
Homo sapiens
37°C, pH 6.20
-
0.0049 - 0.0066
6-(1H-indol-3-yl)isoquinoline
Homo sapiens
37°C, pH 6.7
-
0.0128 - 0.0169
6-(1H-indol-3-yl)quinazoline
Homo sapiens
37°C, pH 6.8
-
0.0017
6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00086
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00204
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.05841
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
Homo sapiens
22°C, pH 6.5
-
0.00311
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.01044
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00022
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00185
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00745
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00606
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00417
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.0061 - 0.0087
6-fluoro-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-1H-indole
Homo sapiens
37°C, pH 6.5
-
0.0127 - 0.0229
7-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one
Homo sapiens
37°C, pH 6.10
-
0.0056 - 0.0071
7-(1H-indol-3-yl)isoquinoline
Homo sapiens
37°C, pH 6.6
-
0.0212 - 0.0326
7-(1H-indol-3-yl)quinazoline
Homo sapiens
37°C, pH 6.9
-
0.00602
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00113
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00006
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
Homo sapiens
pH and temperature not specified in the publication
-
0.00037
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
Homo sapiens
pH and temperature not specified in the publication
-
0.00287
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.00099
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.0003
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
Homo sapiens
pH and temperature not specified in the publication
-
0.01259
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.00777
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
22°C, pH 6.5
-
0.00045
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
Homo sapiens
22°C, pH 6.5
-
0.00019
N-methyl-4-phenyl-1,2-oxazol-5-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.04487
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00036
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00091
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00136
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.1738
[5-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetic acid
Homo sapiens
37°C, pH 6.29
-
0.1045
[6-(1H-indol-3-yl)-1H-benzotriazol-1-yl]acetic acid
Homo sapiens
37°C, pH 6.30
-
0.00033
4-(3-chlorophenyl)-imidazole
Homo sapiens
pH and temperature not specified in the publication
-
0.00011
4-chlorophenyl-1,2,3-triazol-4-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.00048
4-phenylimidazole
Homo sapiens
pH and temperature not specified in the publication
additional information
additional information
-
0.002 - 0.0034
6-(1H-indol-3-yl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.11
-
0.00602
6-(1H-indol-3-yl)-1H-benzotriazole
Homo sapiens
37°C, pH 6.15
-
additional information
additional information
Homo sapiens
the enzymatic and cellular assays are influenced by many factors including detection product, reaction time and culture medium, which may cause the inconsistency of enzymatic and cellular inhibitory activities of test compounds. The IC50 values of all the test compounds derived from NFK assay are 2-3 times higher than that of Kyn adduct assay
-
additional information
additional information
Homo sapiens
-
the enzymatic and cellular assays are influenced by many factors including detection product, reaction time and culture medium, which may cause the inconsistency of enzymatic and cellular inhibitory activities of test compounds. The IC50 values of all the test compounds derived from NFK assay are 2-3 times higher than that of Kyn adduct assay
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Basran, J.; Booth, E.S.; Lee, M.; Handa, S.; Raven, E.L.
Analysis of reaction intermediates in tryptophan 2,3-dioxygenase a comparison with indoleamine 2,3-dioxygenase
Biochemistry
55
6743-6750
2016
Homo sapiens (P48775), Xanthomonas campestris pv. campestris (Q8PDA8), Xanthomonas campestris pv. campestris ATCC 33913 (Q8PDA8)
brenda
Pantouris, G.; Loudon-Griffiths, J.; Mowat, C.G.
Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives
J. Enzyme Inhib. Med. Chem.
31
70-78
2016
Homo sapiens
brenda
Yuasa, H.J.; Ball, H.J.
Efficient tryptophan-catabolizing activity is consistently conserved through evolution of TDO enzymes, but not IDO enzymes
J. Exp. Zool. B
324
128-140
2015
Branchiostoma floridae (C3XXE6), Caenorhabditis elegans (Q09474), Drosophila melanogaster (P20351), Homo sapiens (P48775), Monosiga brevicollis (A9V766), Nematostella vectensis (A7RFF0), no activity in Brugia malayi, no activity in Saccharomyces cerevisiae, no activity in Schistosoma mansoni, Rattus norvegicus (P21643), Strongylocentrotus purpuratus
brenda
Wu, J.S.; Lin, S.Y.; Liao, F.Y.; Hsiao, W.C.; Lee, L.C.; Peng, Y.H.; Hsieh, C.L.; Wu, M.H.; Song, J.S.; Yueh, A.; Chen, C.H.; Yeh, S.H.; Liu, C.Y.; Lin, S.Y.; Yeh, T.K.; Hsu, J.T.; Shih, C.; Ueng, S.H.; Hung, M.S.; Wu, S.Y.
Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening
J. Med. Chem.
58
7807-7819
2015
Homo sapiens (P48775)
brenda
Nienhaus, K.; Hahn, V.; Huepfel, M.; Nienhaus, G.U.
Substrate binding primes human tryptophan 2,3-dioxygenase for ligand binding
J. Phys. Chem. B
121
7412-7420
2017
Homo sapiens (P48775), Homo sapiens
brenda
Gonzalez Esquivel, D.; Ramirez-Ortega, D.; Pineda, B.; Castro, N.; Rios, C.; Perez de la Cruz, V.
Kynurenine pathway metabolites and enzymes involved in redox reactions
Neuropharmacology
112
331-345
2017
Homo sapiens (P14902), Homo sapiens (P48775), Homo sapiens (Q6ZQW0), Mus musculus (P28776), Xanthomonas campestris pv. campestris (Q8PDA8), Xanthomonas campestris pv. campestris ATCC 33913 (Q8PDA8)
brenda
Meng, B.; Wu, D.; Gu, J.; Ouyang, S.; Ding, W.; Liu, Z.
Structural and functional analyses of human tryptophan 2,3-dioxygenase
Proteins
82
3210-3216
2014
Homo sapiens (P48775), Homo sapiens
brenda
Lewis-Ballester, A.; Forouhar, F.; Kim, S.M.; Lew, S.; Wang, Y.; Karkashon, S.; Seetharaman, J.; Batabyal, D.; Chiang, B.Y.; Hussain, M.; Correia, M.A.; Yeh, S.R.; Tong, L.
Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase
Sci. Rep.
6
35169
2016
Homo sapiens (P48775), Homo sapiens
brenda
Pei, Z.; Mendonca, R.; Gazzard, L.; Pastor, R.; Goon, L.; Gustafson, A.; VanderPorten, E.; Hatzivassiliou, G.; Dement, K.; Cass, R.; Yuen, P.W.; Zhang, Y.; Wu, G.; Lin, X.; Liu, Y.; Sellers, B.D.
Aminoisoxazoles as potent inhibitors of tryptophan 2,3-dioxygenase 2 (TDO2)
ACS Med. Chem. Lett.
9
417-421
2018
Homo sapiens (P48775), Homo sapiens
brenda
Liu, Y.; Kim, S.M.; Wang, Y.; Karkashon, S.; Lewis-Ballester, A.; Yeh, S.R.; Correia, M.A.
Characterization of the structural determinants of the ubiquitin-dependent proteasomal degradation of human hepatic tryptophan 2,3-dioxygenase
Biochem. J.
478
1999-2017
2021
Homo sapiens (P48775), Homo sapiens
brenda
Zhang, S.; Guo, L.; Yang, D.; Xing, Z.; Li, W.; Kuang, C.; Yang, Q.
Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)
Bioorg. Chem.
104
104348
2020
Homo sapiens (P48775), Homo sapiens
brenda
Li, Y.; Zhang, S.; Wang, R.; Cui, M.; Liu, W.; Yang, Q.; Kuang, C.
Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase
Bioorg. Med. Chem. Lett.
30
127159
2020
Homo sapiens (P48775)
brenda
Chang, Y.; Han, P.; Wang, Y.; Jia, C.; Zhang, B.; Zhao, Y.; Li, S.; Li, S.; Wang, X.; Yang, X.; Wei, W.
Tryptophan 2,3-dioxygenase 2 plays a key role in regulating the activation of fibroblast-like synoviocytes in autoimmune arthritis
Br. J. Pharmacol.
179
3024-3042
2022
Rattus norvegicus (P21643), Homo sapiens (P48775)
brenda
Boros, F.A.; Vecsei, L.
Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinsons disease
Expert Opin. Ther. Targets
25
877-888
2021
Homo sapiens (P48775)
brenda
Kozlova, A.; Thabault, L.; Liberelle, M.; Klaessens, S.; Prevost, J.R.C.; Mathieu, C.; Pilotte, L.; Stroobant, V.; Van den Eynde, B.; Frederick, R.
Rational design of original fused-cycle selective inhibitors of tryptophan 2,3-dioxygenase
J. Med. Chem.
64
10967-10980
2021
Homo sapiens (P48775)
brenda
Ning, X.L.; Li, Y.Z.; Huo, C.; Deng, J.; Gao, C.; Zhu, K.R.; Wang, M.; Wu, Y.X.; Yu, J.L.; Ren, Y.L.; Luo, Z.Y.; Li, G.; Chen, Y.; Wang, S.Y.; Peng, C.; Yang, L.L.; Wang, Z.Y.; Wu, Y.; Qian, S.; Li, G.B.
X-ray structure-guided discovery of a potent, orally bioavailable, dual human indoleamine/tryptophan 2,3-dioxygenase (hIDO/hTDO) inhibitor that shows activity in a mouse model of Parkinsons disease
J. Med. Chem.
64
8303-8332
2021
Homo sapiens (P48775), Homo sapiens
brenda
Sari, S.; Tomek, P.; Leung, E.; Reynisson, J.
Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening
Molecules
24
4346
2019
Homo sapiens (P48775), Homo sapiens
brenda
Dolsak, A.; Gobec, S.; Sova, M.
Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets
Pharmacol. Ther.
221
107746
2021
Homo sapiens, Homo sapiens (P14902), Homo sapiens (Q6ZQW0)
brenda
Klaessens, S.; Stroobant, V.; Hoffmann, D.; Gyrd-Hansen, M.; Pilotte, L.; Vigneron, N.; De Plaen, E.; Van den Eynde, B.J.
Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase
Proc. Natl. Acad. Sci. USA
118
e2022447118
2021
Homo sapiens (P48775)
brenda
Hutchinson, A.P.; Yin, P.; Neale, I.; Coon, J.S.; Kujawa, S.A.; Liu, S.; Bulun, S.E.
Tryptophan 2,3-dioxygenase-2 in uterine Leiomyoma dysregulation by MED12 mutation status
Reprod. Sci.
29
743-749
2022
Homo sapiens (P48775)
brenda